Concepedia

Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study

Davide Giuseppe Ribaldone, L Parisio, Angela Variola, Fabrizio Bossa, Fabiana Castiglione, Manuela Marzo, Nicole Piazza, Annalisa Aratari, Edoardo Savarino, Giorgia Bodini,

Digestive and Liver Disease · 2023 · 17 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis

Kenneth W. Schroeder, William J. Tremaine, Duane M. Ilstrup · New England Journal of Medicine · 1987 · 3K citations

, , +14

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

William J. Sandborn, Filip Baert, Silvio Danese et al. · Gastroenterology · 2019 · 317 citations · Full text

, , +15

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Séverine Vermeire, Geert D’Haens, Filip Baert et al. · Journal of Crohn s and Colitis · 2021 · 170 citations · Full text

, , +13

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Erwin Dreesen, Bram Verstockt, Sumin Bian et al. · Clinical Gastroenterology and Hepatology · 2018 · 155 citations

, , +12

How do patients with inflammatory bowel disease want their biological therapy administered?

Patrick B. Allen, H Lindsay, Tony Tham · BMC Gastroenterology · 2010 · 127 citations · Full text

, , +14